Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Correction: SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population.
Journal: Diabetologia
Published: May 22, 2026
Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.
Journal: Diabetes, obesity & metabolism
Published: April 01, 2025
Type 2 Diabetes Management in Aotearoa New Zealand: A Comparison of Urban and Rural Primary Care Clinics.
Journal: The Australian journal of rural health
Published: April 01, 2025
Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand.
Journal: BMC health services research
Published: February 27, 2024
Inclusion of ethnicity in Special Authority criteria improves access to medications for Māori and Pacific peoples with type 2 diabetes.
Journal: The New Zealand medical journal
Published: July 28, 2023
Showing 1-6 of 6
Last Updated: 09/26/2026